Efficacy of dupilumab on chronic rhinosinusitis with nasal polyps and concomitant asthma in biologic-naive and biologic-pretreated patients

Objectives Dupilumab, an anti-IL-4 receptor monoclonal antibody (mAb), was recently approved for the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP). The main objective of this study was to assess whether previous exposure to biological treatment affected the clinical outcomes...

Full description

Bibliographic Details

Published in:	Annals of Medicine
Main Authors:	María Sandra Domínguez-Sosa, María Soledad Cabrera-Ramírez, Miriam del Carmen Marrero-Ramos, Delia Dávila-Quintana, Carlos Cabrera-López, Heleia González Cuervo, Jesús Javier Benítez del Rosario, Teresa Carrillo-Díaz
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Subjects:	Chronic rhinosinusitis nasal polyps dupilumab monoclonal antibody perennial allergen sensitization
Online Access:	https://www.tandfonline.com/doi/10.1080/07853890.2024.2411018